Shilpa Medicare Limited, a leading player in pharmaceuticals and biotechnology, through its wholly-owned subsidiary Shilpa Biocare Private Limited, has entered into a strategic partnership with Finland-based Orion Corporation. This collaboration involves out-licensing Shilpa’s flagship product, Recombinant Human Albumin, for commercialization across the European market. Currently under development, the product represents a significant advancement in life-saving biopharmaceuticals.

Under the agreement, Orion will hold exclusive rights for marketing, distribution, and sales throughout Europe, while Shilpa will receive milestone payments tied to development and regulatory achievements. Shilpa has invested nearly eight years in developing this novel biosimilar and has established a large-scale fermentation facility to meet global demand. This partnership is a landmark in Shilpa’s global expansion, leveraging Orion’s robust regional presence and expertise to enhance patient access to next-generation biologics.

Together, both companies reaffirm their commitment to advancing biotechnology-driven therapies and delivering safer, sustainable treatment options to patients worldwide.